RBC maintains Kos at outperform

Kos Pharmaceuticals, Inc. was kept at an outperform, average risk rating and a $55 price target by RBC Capital Markets analyst Ken Trbovich. Kos' FAST-1 trial failed to show a statistically significant difference between Icatibant and a placebo in the primary endpoint, and the FAST-2 trial used an unapproved comparator. Jerini found that the combined analysis shows a statistically significant reduction in time to onset of symptom relief in agnioedema. While there is a need for such products, RBC believes Jerini will need to conduct at least one more study. The best case is an approvable letter next June. Shares of the Cranbury, N.J.-based pharmaceutical company were down $1.79, or 3.65%, at $47.28. (Nasdaq: KOSP)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.